Drug Profile
Birch triterpenes - Amryt Pharma
Alternative Names: AP 101; Betulin-based oleogel; Episalvan; FILSUVEZ; Filsuvez; Oleogel-S10; SericareLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Birken GmbH
- Developer Amryt Pharma
- Class Herbal medicines; Skin disorder therapies; Triterpenes
- Mechanism of Action Keratinocyte modulators; Transient receptor potential channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Epidermolysis bullosa
- Registered Wounds
- Phase III Burns
- Phase II Actinic keratosis; Radiodermatitis
Most Recent Events
- 19 Dec 2023 Registered for Epidermolysis bullosa (In adolescents, In adults, In children, In the elderly) in USA (Topical)
- 12 Apr 2023 Amryt Pharma has been acquired by Chiesi Farmaceutici
- 08 Sep 2022 Registered for Epidermolysis bullosa (In adolescents, In children, In the elderly, In adults, In infants) in United Kingdom (Topical)